Stay informed on developments in cancer and oncology diagnosis, prevention and treatment through these curated webinars. As the race toward a cure for cancer continues, advances in cancer research are constantly revealed as innovation in the field of oncology progresses.
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...
Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype account...
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance. How tumors transition between...
Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is...
The proportion of cell-free DNA (cfDNA) derived from tumor cells in the plasma of patients with cancer is typically less than 2%. To overcome this limitation, methods have been developed to...
In this webinar, we will be discussing some of our most recent testing using our Cas9 proteins, Cas9 RNP nickases in a variety of human cell types, including primary T-cells. Cas nucleases wh...
Individuals of under-represented minority ancestry are at disproportional risk for higher incidence and mortality rates for particular cancers. The unequal burden of cancer in certain racial...
This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used al...
Robotic partial nephrectomy (RPN) has increasingly been applied to the treatment of small renal masses. Because of space limitations and the size of the robot at the patient side, the standa...
Join Branden Hopkinson, Product Marketing Manager at Visiopharm, who will talk about using AI classifiers to find patterns in your images and which artificial intelligence method will work b...
In the past two decades a small number of infrequently dividing cells have been proposed as the source of multi-drug resistance during cancer treatment. These cells identified by their expres...
Metastatic prostate cancer (mPC) is a phenotypically diverse disease with poor responses to immune based therapeutics. Development of immunotherapeutic strategies for mPC is hampered by the...
Triple Negative Breast Cancer (TNBC) is an aggressive form of breast cancer, characterized by the characteristic lack of receptors such as human epidermal growth factor receptor-2 (HER-2), t...
Background: Localized prostate cancer is notable for tumor heterogeneity, and immune heterogeneity within tumor versus benign areas. B7-H3, a member of the B7 superfamily, is highly expresse...
Antibodies have become one of the most important tools in life science research, allowing the detection, quantitation, and determination of changes in proteins and other molecules with respe...
The first small molecule inhibitor of the molecular chaperone Heat Shock Protein 90 (HSP90) was identified more than 20 years ago. Upon determination of the drug binding site and clarificatio...
Mr. Getson, a USA immigration lawyer, focuses on EB-1A(Extraordinary ability) and NIW (National Interest Waiver) cases, the primary categories in which scientific researchers qualify for gree...
Non-small cell lung cancer (NSCLC) accounts for more deaths than colon, breast, and prostate cancers combined. Of patients with NSCLC, 20% initially present with stage I or II disease, for w...
This lecture will encompass the learning experience I have had over my 14,000 RALP cases. We will present an evidence based prospective data collection and analysis of RALP outcomes. We will...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
Activating mutations in PIK3CA are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To characterize determinants...
Blockade of CTLA-4 and PD-1, members of the B7/CD28 family, have proven to be the most successful cancer immunotherapies to date. While the current therapeutic focus remains on B7/CD28 family...
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput fl...
As the most common female malignancy, breast cancer is the most likely reason that a woman will die of cancer around the world. Breast cancer mortality has dropped in the U.S. by 35% since 19...
In prior work, we have pursued how tumor reactive monoclonal antibody (mAb), together with activators of innate immune cells, like NK cells, can augment antibody dependent cell-mediated cytot...
Learning Objectives: 1. To provide an overview of relevant hereditary cancer syndromes 2. To encourage providers to obtain a thorough family history 3. To educate providers about available r...
